Hangzhou Diagens Biotechnology Co., Ltd. (DIAGENS-B) filed a resubmitted monthly return with Hong Kong Exchanges and Clearing on 22 April 2026, covering the period to 31 March 2026—the company’s first reporting period after its Main Board debut on 30 March 2026.

Total registered share capital remained unchanged at 88.88 million H shares with a par value of RMB 1 each. No issues, cancellations, conversions, repurchases or treasury share movements occurred during the period, leaving issued shares and treasury shares at 88.88 million and zero, respectively.

The company confirmed that its public float exceeded the initial prescribed threshold of 17.05% of issued H shares, meeting Main Board Rule 13.32B requirements.

DIAGENS-B reported no outstanding share options, warrants, convertible instruments or other equity-linked agreements as of 31 March 2026.

Executive Director Song Ning signed the statutory confirmations that all regulatory, legal and listing conditions related to the company’s securities have been fully observed.